Pharmacokinetics of Monoclonal Antibodies
10.1007/bf03259352
Crossref journal-article
Springer Science and Business Media LLC
Clinical Immunotherapeutics (297)
Bibliography

Pedley, R. B. (1996). Pharmacokinetics of Monoclonal Antibodies. Clinical Immunotherapeutics, 6(1), 54–67.

Authors 1
  1. R. Barbara Pedley (first)
References 105 Referenced 3
  1. Chester KA, Hawkins RE. Advances in antibody technology for targeted cancer therapy. Tumour Marker Update 1994; 6: 187–95 / Tumour Marker Update by KA Chester (1994)
  2. Mach J-P, Carrel S, Merenda C, et al. In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature 1974; 248: 704–6 (10.1038/248704a0) / Nature by J-P Mach (1974)
  3. Jain RK. Transport of molecules in the tumour interstitium: a review. Cancer Res 1987; 47: 3039–51 / Cancer Res by RK Jain (1987)
  4. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991; 51: 3119–30 / Cancer Res by F Yuan (1991)
  5. Pedley RB, Begent RHJ, Boden JA, et al. Relationship between tumour size and uptake of radiolabelled anti-CEA antibody in a colon tumour xenograft. Eur J Nucl Med 1987; 13: 197–202 (10.1007/BF00256491) / Eur J Nucl Med by RB Pedley (1987)
  6. Sedlacek H-H, Seemann G, Hoffmann D, et al., editors. Antibodies as carriers of cytotoxicity. Basel: Karger, 1992 / Antibodies as carriers of cytotoxicity (1992)
  7. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497–515 (10.1200/JCO.1994.12.7.1497) / J Clin Oncol by RO Dillman (1994)
  8. Hale G, Dyer MJS, Clark MR, et al. Remission induction in non-Hodgkin’s lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; II: 1394–9 (10.1016/S0140-6736(88)90588-0) / Lancet by G Hale (1988)
  9. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994; 343: 1177–83 (10.1016/S0140-6736(94)92398-1) / Lancet by G Riethmuller (1994)
  10. Ragnhammar P, Fagerberg J, Frodin J-E, et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma — long-lasting, complete remissions can be induced. Int J Cancer 1993; 53: 751–8 (10.1002/ijc.2910530508) / Int J Cancer by P Ragnhammar (1993)
  11. Begent RHJ. Targeted therapies: cell surface targets. In: Ponder B, Waring MJ, editors. The science of cancer treatment (cancer biology and medicine) vol 2. Dordrecht: Kluwer Academic Publications, 1990: 161–84 (10.1007/978-94-009-0709-6_9) / The science of cancer treatment (cancer biology and medicine) by RHJ Begent (1990)
  12. Herlyn D, Wettendorff M, Schmoll E, et al. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 1987; 84: 8055–9 (10.1073/pnas.84.22.8055) / Proc Natl Acad Sci USA by D Herlyn (1987)
  13. Durrant LG, Buckley D, Denton GWL, et al. Enhanced cell mediated tumour killing in patients immunised with human monoclonal anti-idiotype antibody. Cancer Res 1994; 54: 4837–40 / Cancer Res by LG Durrant (1994)
  14. Mittelman A, Chen ZY, Yang H, et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992; 89: 466–70 (10.1073/pnas.89.2.466) / Proc Natl Acad Sci USA by A Mittelman (1992)
  15. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys 1993; 20 Pt 2: 551–67 (10.1118/1.597142) / Med Phys by DJ Buchsbaum (1993)
  16. Reilly RM. Radioimmunotherapy of malignancies. Clin Pharm 1991; 10: 359–75 / Clin Pharm by RM Reilly (1991)
  17. Sharkey RM, Pykett MJ, Siegel JA, et al. Radioimmunotherapy of the GW-39 human colonic tumour xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987; 47: 5672–7 / Cancer Res by RM Sharkey (1987)
  18. Buchegger F, Vacca F, Carrel S, et al. Radioimmunotherapy of human colon carcinoma by 131I labeled monoclonal anti-CEA antibodies in the nude mouse model. Int J Cancer 1988; 41: 127–34 (10.1002/ijc.2910410123) / Int J Cancer by F Buchegger (1988)
  19. Pedley RB, Boden JA, Boden R, et al. Comparative radioimmunotherapy using intact or F(ab′)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer 1993; 68: 69–73 (10.1038/bjc.1993.288) / Br J Cancer by RB Pedley (1993)
  20. Jurcic JG, Scheinberg DA. Recent developments in the radioimmunotherapy of cancer. Curr Opin Immunol 1994; 6: 715–21 (10.1016/0952-7915(94)90074-4) / Curr Opin Immunol by JG Jurcic (1994)
  21. Lane DM, Eagle KF, Begent RHJ, et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br J Cancer 1994; 70: 521–5 (10.1038/bjc.1994.338) / Br J Cancer by DM Lane (1994)
  22. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with 131I anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459–65 (10.1056/NEJM199308123290703) / N Engl J Med by MS Kaminski (1993)
  23. Press OW, Eary JF, Appelbaum FR, et al. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–22 (10.1056/NEJM199310213291702) / N Engl J Med by OW Press (1993)
  24. Beaumier PL, Venkatesan P, Vanderheyden J-L, et al. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 1991; 51: 676–81 / Cancer Res by PL Beaumier (1991)
  25. Gerretsen M, Visser GWM, Walsum M, et al. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 1993; 53: 3524–9 / Cancer Res by M Gerretsen (1993)
  26. Smith A, Alberto R, Blaeuenstein P et al. Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. Cancer Res 1993; 53: 5727–33 / Cancer Res by A Smith (1993)
  27. DeNardo GL, DeNardo SJ, Meares CF, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potent therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibody Immunoconjug Radiopharm 1991; 4: 777–85 / Antibody Immunoconjug Radiopharm by GL DeNardo (1991)
  28. King DJ, Turner A, Farnsworth APH, et al. Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994; 54: 6176–85 / Cancer Res by DJ King (1994)
  29. Turner A, King DJ, Farnsworth APH, et al. Comparative biodistribution of indium-Ill-labelled macrocycle chimeric B72.3 antibody in tumour-bearing mice. Br J Cancer 1994; 70: 35–41 (10.1038/bjc.1994.246) / Br J Cancer by A Turner (1994)
  30. Woo DV, Li D, Mattis JA, et al. Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1A in human cancer cells. Cancer Res 1989; 49: 2952–8 / Cancer Res by DV Woo (1989)
  31. Harrison A, Royle L. Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma. Natl Cancer Inst Monogr 1987; 3: 157–8 / Natl Cancer Inst Monogr by A Harrison (1987)
  32. Zalutsky MR, McLendon RE, Garg PK, et al. Radioimmunotherapy of neoplastic meningitis in rats using an α-particleemitting immunoconjugate. Cancer Res 1994; 54: 4719–25 / Cancer Res by MR Zalutsky (1994)
  33. Huneke RB, Pippin CG, Squire RA, et al. Effective α-particlemediated radioimmunotherapy of murine leukemia. Cancer Res 1992; 52: 5818–20 / Cancer Res by RB Huneke (1992)
  34. Hartmann F, Horak EM, Garmestani K, et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor α-expressing lymphoma utilising the α-emitting radionuclideconjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 1994; 54: 4362–70 / Cancer Res by F Hartmann (1994)
  35. Zalutsky MR. Antibody-mediated radiotherapy: future prospects. In: Zalutzky MR, editor. Antibodies in radiodiagnostics and therapy. Boca Raton (FL): CRC Press, 1989 / Antibodies in radiodiagnostics and therapy by MR Zalutsky (1989)
  36. Blumenthal RD, Sharkey RM, Haywood L, et al. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res 1992; 52: 6036–44 / Cancer Res by RD Blumenthal (1992)
  37. O’Dwyer PJ, Mojzisik CM, Hinkle G, et al. Intraoperative probe-directed radio-immunodetection using a monoclonal antibody. Arch Surg 1986; 121: 1391–4 (10.1001/archsurg.1986.01400120037005) / Arch Surg by PJ O’Dwyer (1986)
  38. Theodorou NA. Radioimmunoguided surgery for colorectal cancer. Proceedings of the Tufton Trust Conference on New Antibody Technology and the Emergence of Useful Cancer Therapy; 1994 Oct 10–11: London. London: Royal Society of Medicine, 1995: 51–2 / Radioimmunoguided surgery for colorectal cancer by NA Theodorou (1995)
  39. Paganelli G, Stella M, De Nardi P, et al. A new method for faster blood clearance in radioimmuno-guided surgery. J Nucl Med Allied Sci 1990; 35: 88–9 / J Nucl Med Allied Sci by G Paganelli (1990)
  40. Paganelli G, Belloni C, Magnani P, et al. Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19: 322–9 (10.1007/BF00177053) / Eur J Nucl Med by G Paganelli (1992)
  41. Bamias A, Bowles MJ, Krausz T, et al. Intravesical administration of indium111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer 1993; 54: 899–903 (10.1002/ijc.2910540604) / Int J Cancer by A Bamias (1993)
  42. Roeske JC, Chen TY, Brill AB. Dosimetry of intraperitoneally administered radiolabelled antibodies. Med Phys 1993; 20 Pt 2: 593–600 (10.1118/1.597054) / Med Phys by JC Roeske (1993)
  43. Britton KE. Overview of radioimmunotherapy: a European perspective. Antibody Immunoconjug Radiopharm 1991; 4 Pt 2: 133–50 / Antibody Immunoconjug Radiopharm by KE Britton (1991)
  44. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403–6 (10.1038/bjc.1993.349) / Br J Cancer by V Hird (1993)
  45. Pedley RB, Begent RHJ, Boden JA, et al. The effect of radiosensitizers on radioimmunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft model. Int J Cancer 1991; 47: 597–602 (10.1002/ijc.2910470420) / Int J Cancer by RB Pedley (1991)
  46. Langmuir VK, Mendonca HL. The combined use of 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiat Res 1992; 132: 351–8 (10.2307/3578244) / Radiat Res by VK Langmuir (1992)
  47. Ghetie M-A, Vitetta ES. Recent developments in immunotoxin therapy. Curr Opin Immunol 1994; 6: 707–14 (10.1016/0952-7915(94)90073-6) / Curr Opin Immunol by M-A Ghetie (1994)
  48. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22 deglycosylated ricin A chain immunotoxin in the treatment of B cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624–33 (10.1182/blood.V82.9.2624.2624) / Blood by PL Amlot (1993)
  49. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles. Immunol Today 1993; 14: 252–9 (10.1016/0167-5699(93)90041-I) / Immunol Today by ES Vitetta (1993)
  50. Zangemeisterwittke U, Collinson AR, Fisch I, et al. Anti-tumour activity of a blocked ricin immunotoxin with specificity against the cluster-5a antigen associated with human small-cell lung cancer. Int J Cancer 1993; 54: 1028–35 (10.1002/ijc.2910540628) / Int J Cancer by U Zangemeisterwittke (1993)
  51. Kreitman RJ, Hansen HJ, Jones AL, et al. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab′ induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res 1993; 53: 819–25 / Cancer Res by RJ Kreitman (1993)
  52. Debinski W, Pastan I. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Res 1992; 52: 5379–85 / Cancer Res by W Debinski (1992)
  53. Siegall CB, Chace D, Mixan B, et al. In vitro and in vivo characterization of BF96 sFv-PE40. J Immunol 1994; 152: 2377–84 (10.4049/jimmunol.152.5.2377) / J Immunol by CB Siegall (1994)
  54. Koppel GA. Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. Bioconjug Chem 1990; 1: 13–21 (10.1021/bc00001a002) / Bioconjug Chem by GA Koppel (1990)
  55. Hinman LM, Hamann PR, Wallace R, et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumour antibiotics. Cancer Res 1993; 53: 3336–42 / Cancer Res by LM Hinman (1993)
  56. Shih LB, Xuan H, Sharkey RM, et al. A fluouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model. Int J Cancer 1990; 46: 1101–6 (10.1002/ijc.2910460625) / Int J Cancer by LB Shih (1990)
  57. Huennekens FM. Tumour targeting: activation of prodrugs by enzyme monoclonal antibody conjugates. Trends Biotechnol 1994; 12: 234–9 (10.1016/0167-7799(94)90122-8) / Trends Biotechnol by FM Huennekens (1994)
  58. Begent RHJ, Pedley RB. Monoclonal antibody administration: current clinical pharmacokinetic status and future trends. Clin Pharmacokinet 1992; 23 Pt 2: 85–9 (10.2165/00003088-199223020-00001) / Clin Pharmacokinet by RHJ Begent (1992)
  59. Buchegger F, Pelegrin A, Delaloye B, et al. Iodine-131-labeled MAb F(ab′)2 fragments are more efficient and less toxic than intact CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990; 31: 1035–44 / J Nucl Med by F Buchegger (1990)
  60. Schott ME, Frazier KA, Pollock DK, et al. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumour antibody fragments. Bioconjug Chem 1993; 4: 153–65 (10.1021/bc00020a008) / Bioconjug Chem by ME Schott (1993)
  61. Pedley RB, Boden JA, Boden R, et al. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994; 70: 1126–30 (10.1038/bjc.1994.459) / Br J Cancer by RB Pedley (1994)
  62. Kitamura K, Takahashi TK, Yamaguchi T, et al. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer therapy. Cancer Res 1991; 51: 4310–5 / Cancer Res by K Kitamura (1991)
  63. Delgardo C, Pedley RB, Herraez A, et al. Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab′ fragment by poly(ethylene glycol) (PEG)-modification. Br J Cancer 1996; 73: 175–82 (10.1038/bjc.1996.32) / Br J Cancer by C Delgardo (1996)
  64. Marshall D, Pedley RB, Boden JA, et al. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer 1996; 73: 565–72 (10.1038/bjc.1996.99) / Br J Cancer by D Marshall (1996)
  65. McCafferty J, Griffiths J, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552–4 (10.1038/348552a0) / Nature by J McCafferty (1990)
  66. Chester KA, Begent RHJ, Robson L, et al. Phage libraries for the generation of clinically useful antibodies. Lancet 1994; 343: 455–6 (10.1016/S0140-6736(94)92695-6) / Lancet by KA Chester (1994)
  67. Yokata T, Milenik DE, Whitlow M, et al. Rapid tumour penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402–8 / Cancer Res by T Yokata (1992)
  68. Savage P, So A, Spooner RA, et al. A recombinant single-chain Fv antibody interleukin-2 fusion protein. Br J Cancer 1993; 67: 304–10 (10.1038/bjc.1993.57) / Br J Cancer by P Savage (1993)
  69. Michael NP, Chester KA, Melton RG, et al. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2-anti-CEA scFv fusion protein. Immunotechnology 1996; 2: 47–57 (10.1016/1380-2933(96)00033-4) / Immunotechnology by NP Michael (1996)
  70. Begent RHJ, Bagshawe KD, Green AJ, et al. Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet 1982; II: 739–42 (10.1016/S0140-6736(82)90923-0) / Lancet by RHJ Begent (1982)
  71. Begent RHJ, Bagshawe KD, Pedley RB, et al. Use of second antibody in radioimmunotherapy. Natl Cancer Inst Monogr 1987; 3: 59–61 / Natl Cancer Inst Monogr by RHJ Begent (1987)
  72. Goldenberg DM, Sharkey RM, Ford E. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med 1987; 28: 1604–10 / J Nucl Med by DM Goldenberg (1987)
  73. Pedley RB, Dale R, Boden JA, et al. The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumour xenograft model. Int J Cancer 1989; 43: 713–18 (10.1002/ijc.2910430429) / Int J Cancer by RB Pedley (1989)
  74. Marshall D, Pedley RB, Boden JA, et al. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br J Cancer 1994; 69: 502–7 (10.1038/bjc.1994.91) / Br J Cancer by D Marshall (1994)
  75. Marshall D, Pedley RB, Melton RG, et al. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab′)2 fragments of an antitumour antibody. Br J Cancer 1995; 71: 18–24 (10.1038/bjc.1995.5) / Br J Cancer by D Marshall (1995)
  76. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumour targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960–6 / Cancer Res by G Paganelli (1991)
  77. Khawli LA, Alauddin MM, Miller GK, et al. Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabelled streptavidin. Antibody Immunoconjug Radiopharm 1993; 6: 13–27 / Antibody Immunoconjug Radiopharm by LA Khawli (1993)
  78. Saga T, Weinstein JN, Jeong JM, et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabelled streptavidin. Cancer Res 1994; 54: 2160–5 / Cancer Res by T Saga (1994)
  79. Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 1987; 56: 531–2 (10.1038/bjc.1987.237) / Br J Cancer by KD Bagshawe (1987)
  80. Senter PD, Wallace PM, Svensson HP, et al. Generation of cytotoxic agents by targeted enzymes. Bioconjug Chem 1993; 4: 3–9 (10.1021/bc00019a001) / Bioconjug Chem by PD Senter (1993)
  81. Deonarain MP, Epenetos AA. Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer 1994; 70: 786–94 (10.1038/bjc.1994.400) / Br J Cancer by MP Deonarain (1994)
  82. Springer CJ, Niculescu-Duvaz I, Mauger AB, et al. The design of prodrugs for antibody-directed enzyme therapy (ADEPT). Proceedings of the Tufton Trust Conference on New Antibody Technology and the Emergence of Useful Cancer Therapy; 1994 Oct 10–11: London. London: Royal Society, of Medicine, 1995: 75–7 / The design of prodrugs for antibody-directed enzyme therapy (ADEPT) by CJ Springer (1995)
  83. Bagshawe KD. Antibody-directed enzyme prodrug therapy: a review. Drug Dev Res 1995; 34: 220–30 (10.1002/ddr.430340211) / Drug Dev Res by KD Bagshawe (1995)
  84. Springer CJ, Poon GK, Sharma SK, et al. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study. Cell Biophys 1994; 24/25: 193–207 (10.1007/BF02789230) / Cell Biophys by CJ Springer (1994)
  85. Sharma SK, Bagshawe KD, Springer CJ, et al. Antibody-directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Markers 1991; 9: 225–31 / Dis Markers by SK Sharma (1991)
  86. Bagshawe KD, Sharma SK, Springer CJ, et al. Antibody-directed prodrug therapy (ADEPT): a pilot scale clinical therapy. Tumor Targeting 1995; 1: 17–29 / Tumor Targeting by KD Bagshawe (1995)
  87. Le Doussal JM, Gruaz-Guyon A, Martin M, et al. Targetting of indium-111-labelled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumours hosted in nude mice. Cancer Res 1990; 50: 3445–52 / Cancer Res by JM Doussal Le (1990)
  88. Pimm MV, Robins RA, Embleton MJ, et al. A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexatecarrier conjugate. Br J Cancer 1990; 61: 508–13 (10.1038/bjc.1990.115) / Br J Cancer by MV Pimm (1990)
  89. Renner C, Jung W, Sahin U, et al. Cure of xenografted human tumours by bispecific monoclonal antibodies and human T-cells. Science 1994; 264: 833–5 (10.1126/science.8171337) / Science by C Renner (1994)
  90. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T-cells. Nature 1985; 314: 628–31 (10.1038/314628a0) / Nature by UD Staerz (1985)
  91. Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumour xenografts following irradiation. Cancer Res 1990; 50: 159–63 / Cancer Res by H Kalofonos (1990)
  92. Order SE, Klein JL, Leichner PK, et al. Radiolabelled antibody in the treatment of primary and metastatic liver malignancies. Recent Res Cancer Res 1986; 100: 307–12 (10.1007/978-3-642-82635-1_38) / Recent Res Cancer Res by SE Order (1986)
  93. Folli S, Pelegrin A, Chalandon Y, et al. Tumour-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993: 53: 829–36 (10.1002/ijc.2910530521) / Int J Cancer by S Folli (1993)
  94. Rowlinson-Busza G, Maraveyas A, Epenetos AA. Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model. Br J Cancer 1995; 71: 660–5 (10.1038/bjc.1995.131) / Br J Cancer by G Rowlinson-Busza (1995)
  95. Russell SM, Krauer KG, McKenzie IFC, et al. Effect of tumour necrosis factor on the antitumour efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy. Cancer Res 1990; 50: 6028–33 / Cancer Res by SM Russell (1990)
  96. Smyth MJ, Pieterz A, McKenzie IFC. Increased antitumour effect of immunoconjugates and tumour necrosis factor. Cancer Res 1988; 48: 3607–12 / Cancer Res by MJ Smyth (1988)
  97. Melton RG, Rowland JA, Pietersz GA, et al. Tumour necrosis factor increases tumour uptake of co-administered antibodycarboxypeptidase G2 conjugate. Eur J Cancer 1993; 29A: 1177–83 (10.1016/S0959-8049(05)80311-9) / Eur J Cancer by RG Melton (1993)
  98. Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumours. Cancer 1994; 73: 824–31 (10.1002/1097-0142(19940201)73:3+<824::AID-CNCR2820731312>3.0.CO;2-V) / Cancer by LA Khawli (1994)
  99. Zwi LJ, Baguley BC, Gavin JB, et al. The morphological effects of the antitumour agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumour. Pathology 1994; 26: 161–9 (10.1080/00313029400169411) / Pathology by LJ Zwi (1994)
  100. Ching L–M, Joseph WR, Crosier KE, et al. Induction of tumour necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NCS 640488). Cancer Res 1994; 54: 870–2 / Cancer Res by LM Ching (1994)
  101. Pedley RB, Begent RHJ, Boden JA, et al. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. Int J Cancer 1994; 57: 830–5 (10.1002/ijc.2910570611) / Int J Cancer by RB Pedley (1994)
  102. Pedley RB, Boden JA, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow modifying agents. Cancer Res 1996; in press / Cancer Res by RB Pedley (1996)
  103. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727–35 / Cancer Res by LF Brown (1993)
  104. Kim KJ, Li B, Winer J. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–4 (10.1038/362841a0) / Nature by KJ Kim (1993)
  105. Burrows FJ, Thorpe PE. Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc Natl Acad Sci USA 1993; 90: 8996–9000 (10.1073/pnas.90.19.8996) / Proc Natl Acad Sci USA by FJ Burrows (1993)
Dates
Type When
Created 12 years, 10 months ago (Nov. 3, 2012, 3:56 p.m.)
Deposited 2 years, 2 months ago (June 26, 2023, 10:35 a.m.)
Indexed 2 years, 2 months ago (June 26, 2023, 11:10 a.m.)
Issued 29 years, 2 months ago (July 1, 1996)
Published 29 years, 2 months ago (July 1, 1996)
Published Online 12 years, 10 months ago (Nov. 3, 2012)
Published Print 29 years, 2 months ago (July 1, 1996)
Funders 0

None

@article{Pedley_1996, title={Pharmacokinetics of Monoclonal Antibodies: Implications for Their Use in Cancer Therapy}, volume={6}, ISSN={1172-7039}, url={http://dx.doi.org/10.1007/bf03259352}, DOI={10.1007/bf03259352}, number={1}, journal={Clinical Immunotherapeutics}, publisher={Springer Science and Business Media LLC}, author={Pedley, R. Barbara}, year={1996}, month=jul, pages={54–67} }